- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
Patent holdings for IPC class C07D 231/02
Total number of patents in this class: 80
10-year publication summary
|
4
|
2
|
5
|
6
|
6
|
7
|
5
|
6
|
5
|
6
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme Corp. | 2183 |
5 |
| Novartis AG | 10309 |
4 |
| Celgene Corporation | 1409 |
4 |
| National Institute of Biological Sciences, Beijing | 101 |
3 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3281 |
3 |
| Northwestern University | 3531 |
2 |
| FMC Corporation | 815 |
2 |
| Fox Chase Chemical Diversity Center, Inc. | 15 |
2 |
| Verseon Corporation | 9 |
2 |
| Virginia Commonwealth University | 653 |
2 |
| Praxis Precision Medicines, Inc. | 227 |
2 |
| Nuvalent, Inc. | 89 |
2 |
| Merck Sharp & Dohme LLC | 3732 |
2 |
| Genentech, Inc. | 4098 |
1 |
| Janssen Pharmaceutica N.V. | 3178 |
1 |
| Merck Patent GmbH | 5727 |
1 |
| The Board of Trustees of the Leland Stanford Junior University | 6633 |
1 |
| The Regents of the University of Michigan | 4962 |
1 |
| Vertex Pharmaceuticals Incorporated | 1587 |
1 |
| Mayo Foundation for Medical Education and Research | 3371 |
1 |
| Other owners | 38 |